78 results on '"Cataldi, A"'
Search Results
2. Challenges and Opportunities in IBD Clinical Trial Design
3. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
4. 968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
5. Tu1737 ROLE OF NLRX1 AGONIST NX-13 IN REDUCING VISCERAL HYPERSENSITIVITY IN PRECLINICAL GASTROINTESTINAL INFLAMMATION
6. 635 EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
7. 402 THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN
8. Challenges and Opportunities in IBD Clinical Trial Design
9. 968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
10. Tu1718 A PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL EFFICACY OF THE NUCLEOTIDEBINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
11. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
12. Tu1728 – Long-Term Efficacy and Pharmacodynamics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1) Monoclonal Antibody Shp647 in Crohn's Disease: the Opera Ii Study
13. Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis
14. Tu1727 – Rapidity of Symptomatic and Inflammatory Biomarker Improvements Following Upadacitinib Induction Treatment: Data from the U-Achieve Study
15. Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii
16. 799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve
17. 800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study
18. Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study
19. P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
20. Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii
21. Tu1728 – Long-Term Efficacy and Pharmacodynamics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1) Monoclonal Antibody Shp647 in Crohn's Disease: the Opera Ii Study
22. 800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study
23. Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis
24. 799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve
25. Tu1727 – Rapidity of Symptomatic and Inflammatory Biomarker Improvements Following Upadacitinib Induction Treatment: Data from the U-Achieve Study
26. Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study
27. P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)
28. P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
29. Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study
30. Sa1755 - Rapidity of Clinical and Laboratory Improvements Following Upadacitinib Induction Treatment: Data from the Celest Study
31. Su2010 - The Anti-Madcam Antibody Shp647 in Crohn's Disease: Endoscopic Effects of Induction Therapy
32. Su1803 - Correlation of Endoscopic and Clinical Endpoints During Induction Therapy in Patients with Moderate to Severe Crohn's Disease: Analysis from Celest Study
33. Sa1774 - Incidence of Venous Thromboembolic Complications in Controlled Trials of Inflammatory Bowel Disease
34. Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II Study
35. Sa1755 - Rapidity of Clinical and Laboratory Improvements Following Upadacitinib Induction Treatment: Data from the Celest Study
36. Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II Study
37. Sa1774 - Incidence of Venous Thromboembolic Complications in Controlled Trials of Inflammatory Bowel Disease
38. Su1803 - Correlation of Endoscopic and Clinical Endpoints During Induction Therapy in Patients with Moderate to Severe Crohn's Disease: Analysis from Celest Study
39. Su2010 - The Anti-Madcam Antibody Shp647 in Crohn's Disease: Endoscopic Effects of Induction Therapy
40. Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study
41. Su1925 Feasibility of a Placebo-Controlled, Randomized Mesalamine Withdrawal Study in Children and Adolescents With Ulcerative Colitis
42. Su1925 Feasibility of a Placebo-Controlled, Randomized Mesalamine Withdrawal Study in Children and Adolescents With Ulcerative Colitis
43. 764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders
44. 764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders
45. 901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study
46. 825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study
47. 825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study
48. 901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study
49. Mo1207 Discrepancy Between Fecal Biomarkers and Their Intestinal Gene Expression in Ulcerative Colitis: Results From an Anti-IL-13 Antibody Study
50. 867 Anti-MAdCAM Monoclonal Antibody PF-00547659 Does Not Affect Immune Surveillance in the Central Nervous System of Crohn's Disease Patients Who Are Anti-TNF Inadequate Responders: Results From the Tosca Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.